Pharmacy Week in Review: Asthma Drug Gets Breakthrough Therapy Designation, FDA Ensures Compounding Quality

A look at last week's top stories in the world of pharmacy.

Transcript

Nicole Grassano, Host:

Hello and welcome to the Pharmacy Times

News Network. I’m Nicole Grassano your host for our Pharmacy Week in Review.

The FDA is taking new steps to better ensure the quality of compounded drugs, while also preserving patient access to these medications, Pharmacy Times

reported. In a statement, FDA Commissioner Scott Gottlieb said that the agency’s compounding program, which includes implementation and provisions of the law, is a priority.

In a revised draft memorandum of understanding, the FDA is making changes to its 2018 Compounding Policy Priorities Plan

. The memorandum addresses investigations of complaints related to compounded drug products distributed outside the state, distribution of inordinate amounts of compounded drug products interstate, and submission and disclosure of information.

Patients with asthma with certain genotype combinations demonstrate more intense symptoms when combined with close proximity to roadways, suggesting that traffic-related air pollution exposure may affect the likelihood of asthma diagnosis and exacerbations, Contemporary Clinic reported.

The study, the results of which were published in Scientific Reports

,

considered individual data on genotype, residential address, asthma diagnosis, and exacerbations from the Environmental Polymorphisms Registry.

Patients were divided into 3 groups—hyper-responders, hypo-responders, and neither—and they measured the participants' distance between their residence and nearest major road. Patients with certain genetic profiles had exhibited more intense symptoms following exposure to traffic pollution. Furthermore, patients with asthma who lacked this genetic profile did not have the same sensitivity to traffic pollution and do not experience worse asthma symptoms.

FDA officials recently granted breakthrough therapy designation for tezepelumab in patients with severe asthma without an eosinophilic phenotype, Specialty Pharmacy Times

reported. Tezepelumab is a potential first-in-class drug that blocks thymic stromal lymphopoietin or TSLP, an upstream modulator of multiple inflammatory pathways, according to Amgen.

Blocking TSLP may prevent the release of pro-inflammatory cytokines by immune cells, resulting in the prevention of asthma exacerbations and improved asthma control, Amgen and AstraZeneca said in a statement. The designation is based on data from the phase 2b PATHWAY trial, which showed a significant reduction in the annual asthma exacerbation rate compared with a placebo over a 52-week treatment period.

Pharmacists may get more questions about Ibrance if their patients have seen a new commercial for the prescription to treat breast cancer. In the spot, called “Carla,” it is an ordinary week for her, which makes it special. Even though Carla has metastatic breast cancer, she can still travel to a lakeside cabin with her family. She spends her time picking lavender, playing games, and enjoying her new normal. According to the commercial, Ibrance has been shown to be more effective at delaying her disease than letrozole.

For more great coverage and practical information for today’s pharmacist, visit our website and sign up for our Daily eNews. And don’t forget to follow us on Facebook,

Twitter, and Instagram.

Thanks for watching our Pharmacy Week in Review. I’m Nicole Grassano at the Pharmacy Times

News Network.